GlassScriptPhysician profile
Afiur Hamdi Rahman
NPI 1528583614
$2,136.00
in general payments reported to CMS, 2019-2025
21 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $245 · 2023: $628 · 2024: $552 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Education: $91.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.73 |
| Education | $91.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $351.01 | 2022-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $324.59 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $187.61 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $154.86 | 2022-2025 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $128.35 | 2023-2024 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $109.51 | 2022-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $107.73 | 2022-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $105.55 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $103.51 | 2022-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $86.84 | 2022-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $82.92 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $79.33 | 2023-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.01 | 2023-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $55.37 | 2025 | Yorvipath |
| Akebia Therapeutics INC | $48.24 | 2022-2023 | Auryxia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.21 | 2022-2024 | |
| Ardelyx, INC. | $20.81 | 2023 | Ibsrela |
| Scpharmaceuticals INC. | $19.69 | 2025 | |
| Novo Nordisk INC | $19.15 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.02 | 2023 | Givlaari |
| Lilly USA, LLC | $14.69 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afiur Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.